Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2019 | The value of MRD testing in transplant-eligible patients

MRD testing has proven to be significant in determining treatment endpoint in patients with multiple myeloma. Here, Maria-Victoria Mateos, MD, PhD, of University Hospital of Salamanca, Salamanca, Spain, talks about the value of MRD testing in transplant-eligible patients. Dr Mateos was speaking at the European Society for Blood and Marrow Transplantation (EBMT) 2019 Annual Meeting, held in Frankfurt, Germany.